Combination Therapy Dosing Considerations

# Introduction Combination therapy, the use of two or more therapeutic agents, is a common strategy in the management of various diseases. The goal is to increase therapeutic efficacy, decrease overall drug toxicity, and prevent the development of drug resistance [3][2]. However, dosing considerations for combination therapy are complex and involve understanding the interaction between different drugs, their pharmacokinetics, and their pharmacodynamics. This review will explore the practical considerations for dosing in combination therapy, with a focus on various medical fields including oncology, immunology, and cardiology. # Preclinical Research ## Natural Killer Cell Therapy and Cannabidiol in Oncology Preclinical evidence suggests that natural killer (NK) cell therapy, a type of immunotherapy that uses a patient's immune cells to attack cancer cells, can be effective in treating advanced non-small cell lung cancer [4]. Similarly, another preclinical study found potential therapeutic benefits of cannabidiol (CBD), a non-psychoactive component of the cannabis plant, in lung cancer treatment [8]. However, the dosing considerations for these therapies in combination have yet to be thoroughly investigated in preclinical models. ## Photobiomodulation Therapy in Neuroscience Photobiomodulation therapy, the use of light to stimulate, heal, or protect tissue that has been injured, is another area where dosing considerations for combination therapy have been explored at a preclinical level. Simulation-based dosimetry studies have identified factors such as wavelength, power density, and skin tone as critical considerations for effective photobiomodulation of the human brain [10]. These considerations will likely play a significant role in the development of combination therapies involving photobiomodulation. # Clinical Evidence ## IL-23p19 inhibitors in Inflammatory Bowel Disease In the field of immunology, IL-23p19 inhibitors have shown promise in the treatment of inflammatory bowel disease (IBD). Practical considerations for their use, including dosing, have been explored [1]. However, the evidence for their use in combination with other therapies is not explicitly mentioned in the provided citations. ## Radiotherapy and Radiopharmaceutical Therapy in Oncology Combination therapy involving radiotherapy and radiopharmaceutical therapy has demonstrated potential in the treatment of thyroid cancer [5]. Dosimetry-driven precision medicine is a key consideration in determining the optimal dose of radiopharmaceuticals in combination with radiotherapy [5]. This strategy allows for highly personalized treatment plans that take into account the patient's unique physiological characteristics. ## CDK4/6 Inhibitors in Breast Cancer In the context of breast cancer, combination therapy involving Cyclin-Dependent Kinase 4/6 (CDK4/6) inhibitors has demonstrated significant benefits in HR-Positive, HER2-Negative early breast cancer [2]. Practical guidance for their implementation, including dosing considerations, has been provided in a multidisciplinary context [2]. ## Antihypertensive Drugs in Cardiology In cardiology, the combination of different antihypertensive drugs has been shown to be effective in reducing blood pressure [3]. The review of randomised, double-blind, placebo-controlled trials has provided insights into the blood pressure-lowering efficacy of various combinations [3]. # Safety and Limitations While combination therapy has the potential to improve treatment outcomes, it also presents challenges and risks. These include increased risk of adverse reactions, drug-drug interactions, and more complex patient management [2][3]. In addition, the optimal dosing for combination therapy often varies depending on the specific drugs used, the disease being treated, and the individual patient's characteristics. Consequently, careful consideration and monitoring are required to ensure the safe and effective use of combination therapy. # Key Takeaways Combination therapy is a common strategy employed across multiple medical fields, aiming to increase treatment efficacy and reduce drug toxicity. However, determining the optimal dosing for combination therapy is complex and requires an understanding of drug interactions, pharmacokinetics, and pharmacodynamics. Preclinical research and clinical evidence highlight different dosing considerations in various contexts, including natural killer cell therapy and cannabidiol in oncology, photobiomodulation therapy in neuroscience, IL-23p19 inhibitors in IBD, radiotherapy and radiopharmaceutical therapy in thyroid cancer, CDK4/6 inhibitors in breast cancer, and antihypertensive drugs in cardiology. Nonetheless, safety and limitations associated with combination therapy should not be overlooked, emphasizing the need for careful consideration and monitoring in clinical practice.